- Novartis' ( NYSE: NVS ) board appointed Gilbert Ghostine as chairman-designate of the new board of Sandoz.
- Ghostine has served as CEO of Geneva-based privately owned perfume and taste company Firmenich since 2014.
- Ghostine will take up the role after the spin-off of Sandoz from Novartis in H2 2023, subject to conditions.
- The Swiss pharma giant said Ghostine currently serves on the boards of Danone and Four Seasons Hotels & Resorts.
- In August 2022, Novartis said it was going to spin off its generics and biosimilars division Sandoz into a separate publicly traded standalone company to focus on innovative medicines.
For further details see:
Novartis appoints perfume company Firmenich CEO as chairman-designate of Sandoz